Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Laura M. Pardo, Andrew P. Voigt, Todd A. Alonzo, Elisabeth R. Wilson, Robert B. Gerbing, Dana J. Paine, Fangyan Dai, Andrew J. Menssen, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Denise A. Wells, Lisa Eidenschink Brodersen, Michael R. Loken

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: In patients with acute myeloid leukemia (AML), CD56 expression has been associated with adverse clinical outcome. We reported on a phenotype associated with very poor prognosis (RAM) in children enrolled in the Children's Oncology Group trial AAML0531 (Brodersen et al. Leukemia 30 (2016) 2077–2080). RAM is also characterized in part by high-intensity expression of the CD56 antigen. Herein, we investigate underlying biological and clinical differences among CD56-positive AMLs for patients in AAML0531. Methods: For 769 newly diagnosed pediatric patients with de novo AML enrolled in AAML0531, bone marrow specimens were submitted for flow cytometric analysis. For each patient, an immunophenotypic expression profile (IEP) was defined by mean fluorescent intensities of assayed surface antigens. Unsupervised hierarchical clustering analysis (HCA) was completed to group patients with similar immunophenotypes. Clusters were then evaluated for CD56 expression. Principal component analysis (PCA) was subsequently applied to determine whether CD56-positive patient groups were nonoverlapping. Results: HCA of IEPs revealed three unique phenotypic clusters of patients with CD56-positive AML, and PCA showed that these three cohorts are distinct. Cohort 1 (N = 77) showed a prevalence of t(8;21) patients (72%), Cohort 2 (N = 52) a prevalence of 11q23 patients (69%), and Cohort 3 (RAM) (N = 16) a prevalence of patients with co-occurrence of the CBFA2T3–GLIS2 fusion transcript (63%). The 5-year event-free survival (EFS) for Cohorts 1, 2, and 3 were 69, 39, and 19%, respectively. Conclusions: When leukemia is considered by its multidimensional immunophenotype and not by the expression of a single antigen, correlations are seen between genotype and there are significant differences in patient outcomes.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalCytometry Part B - Clinical Cytometry
Volume98
Issue number1
DOIs
StatePublished - Jan 1 2020

Bibliographical note

Funding Information:
The authors would like to thank the patients and families for participating in AAML0531. We also thank Vani Shanker for scientific editing. This work was supported by St. Baldrick's Foundation and grants U10CA098543 (Chair's grant), U10CA098413 (the Statistical Center Grant), U10CA180886 (NCTN Operations Center Grant), and U10CA180899 (NCTN Statistics & Data Center Grant).

Keywords

  • AML
  • CD56
  • flow cytometry
  • multidimensional immunophenotype
  • pediatric

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this